Cingulate Inc. Warrants
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for th… Read more
Cingulate Inc. Warrants (CINGW) - Total Liabilities
Latest total liabilities as of September 2025: $7.05 Million USD
Based on the latest financial reports, Cingulate Inc. Warrants (CINGW) has total liabilities worth $7.05 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cingulate Inc. Warrants - Total Liabilities Trend (2019–2024)
This chart illustrates how Cingulate Inc. Warrants's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cingulate Inc. Warrants Competitors by Total Liabilities
The table below lists competitors of Cingulate Inc. Warrants ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chapters Group AG
XETRA:CHG
|
Germany | €306.36 Million |
|
Grapefruit USA Inc
PINK:GPFT
|
USA | $9.21 Million |
|
New Momentum Corporation
PINK:NNAX
|
USA | $738.15K |
|
Lanbay Inc
PINK:LNBY
|
USA | $106.62K |
|
Syros Pharmaceuticals Inc
NASDAQ:SYRS
|
USA | $96.12 Million |
|
2G ENERGY - Dusseldorf Stock Exchang
DU:2GB
|
Germany | €103.46 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Cingulate Inc. Warrants's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cingulate Inc. Warrants's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cingulate Inc. Warrants (2019–2024)
The table below shows the annual total liabilities of Cingulate Inc. Warrants from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.41 Million | -28.49% |
| 2023-12-31 | $10.36 Million | +37.72% |
| 2022-12-31 | $7.52 Million | +268.29% |
| 2021-12-31 | $2.04 Million | -54.56% |
| 2020-12-31 | $4.50 Million | -3.64% |
| 2019-12-31 | $4.66 Million | -- |